-
公开(公告)号:US20180030053A1
公开(公告)日:2018-02-01
申请号:US15782722
申请日:2017-10-12
Applicant: Novartis AG
Inventor: Jiping FU , Xianming JIN , Patrick LEE , Peichao LU , Joseph Michael YOUNG
IPC: C07D471/14 , C07D491/147 , A61K31/4375
CPC classification number: C07D471/14 , A61K31/4375 , C07D217/08 , C07D491/14 , C07D491/147
Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
-
公开(公告)号:US20170240548A1
公开(公告)日:2017-08-24
申请号:US15435137
申请日:2017-02-16
Applicant: Novartis AG
Inventor: Jiping FU , Xianming JIN , Patrick LEE , Peichao LU , Joseph Michael YOUNG
IPC: C07D471/14 , C07D491/147 , A61K31/4375
CPC classification number: C07D471/14 , A61K31/4375 , C07D217/08 , C07D491/14 , C07D491/147
Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
-
公开(公告)号:US20170088525A1
公开(公告)日:2017-03-30
申请号:US15375560
申请日:2016-12-12
Applicant: Novartis AG
Inventor: Jiping FU , Xianming JIN , Subramanian KARUR , Guillaume LAPOINTE , Ann Marie MADERA , Zachary Kevin SWEENEY
IPC: C07D261/08 , A61K31/42 , A61K45/06
CPC classification number: C07D261/08 , A61K31/42 , A61K31/422 , A61K45/06 , C07D413/06 , C07D413/12 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , A61K2300/00
Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
-
公开(公告)号:US20220363671A1
公开(公告)日:2022-11-17
申请号:US17642292
申请日:2020-09-16
Applicant: NOVARTIS AG
Inventor: Jake AXFORD , Rohan Eric John BECKWITH , Simone BONAZZI , Nicole BUSCHMANN , Artiom CERNIJENKO , Janetta DEWHURST , Aleem FAZAL , Matthew James HESSE , Lauren HOLDER , Viktor HORNAK , Hidetomo IMASE , Rama JAIN , Xianming JIN , John Ryan KERRIGAN , Julie LACHAL , Fupeng MA , Hasnain Ahmed MALIK , James R. MANNING , Daniel MCKAY , Robert Joseph MOREAU , Pierre NIMSGERN , Gary O'BRIEN , Anna VULPETTI , Ken YAMADA , Junping ZHAO
IPC: C07D405/04 , A61K31/513 , C07D471/04 , C07D413/04 , C07D401/14
Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.
-
公开(公告)号:US20170174640A1
公开(公告)日:2017-06-22
申请号:US15454187
申请日:2017-03-09
Applicant: Novartis AG
Inventor: Jiping FU , Xianming JIN , Subramanian KARUR , Guillaume LAPOINTE , Patrick LEE , Zachary Kevin SWEENEY
IPC: C07D261/04 , C07D413/04 , A61K31/4439 , A61K45/06 , A61K31/5377 , C07D417/10 , A61K31/427 , A61K31/422 , A61K31/42 , C07D413/10
CPC classification number: C07D261/04 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K45/06 , C07D413/04 , C07D413/10 , C07D417/10
Abstract: This invention pertains generally to compounds of Formula I and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention pertains to methods and compositions for treating infections caused by Gram-negative bacteria.
-
公开(公告)号:US20200270265A1
公开(公告)日:2020-08-27
申请号:US15999664
申请日:2017-02-16
Applicant: Novartis AG
Inventor: Jiping FU , Xianming JIN , Patrick LEE , Peichao LU , Joseph Michael YOUNG
IPC: C07D491/147 , C07D471/04 , C07D519/00 , A61P31/20
Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
-
公开(公告)号:US20180030004A1
公开(公告)日:2018-02-01
申请号:US15728351
申请日:2017-10-09
Applicant: Novartis AG
Inventor: Jiping FU , Xianming JIN , Subramanian KARUR , Guillaume LAPOINTE , Ann Marie MADERA , Zachary Kevin SWEENEY
IPC: C07D261/08 , A61K45/06 , A61K31/42 , A61K31/422 , C07D413/12 , C07D413/06
CPC classification number: C07D261/08 , A61K31/42 , A61K31/422 , A61K45/06 , C07D413/06 , C07D413/12 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , A61K2300/00
Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
-
公开(公告)号:US20210346377A1
公开(公告)日:2021-11-11
申请号:US16956527
申请日:2018-12-19
Applicant: Novartis AG
Inventor: Jiping FU , Wooseok HAN , Xianming JIN , Keith Bruce PFISTER , Joseph Michael YOUNG
IPC: A61K31/4985 , C07D471/14 , A01N43/90 , A61K45/06 , A61K47/60 , A61K38/21 , A61P31/20
Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.
-
公开(公告)号:US20190247392A1
公开(公告)日:2019-08-15
申请号:US16210968
申请日:2018-12-05
Applicant: Novartis AG
Inventor: Jeffrey T. BAGDANOFF , Yu DING , Wooseok HAN , Zilin HUANG , Qun JIANG , Xianming JIN , Xiang KOU , Patrick LEE , Mika LINDVALL , Zhongcheng MIN , Yue PAN , Sabina PECCHI , Keith Bruce PFISTER , Daniel POON , Vivek RAUNIYAR , Xiaojing Michael WANG , Qiong ZHANG , Jianguang ZHOU , Shejin ZHU
IPC: A61K31/497 , A61K31/5355 , A61K31/4436 , A61K31/4433 , A61K31/44 , C07D403/06 , C07D401/12 , C07D401/06 , C07D213/73 , C07D413/14 , C07D241/20 , C07D401/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D498/04 , A61K31/4439 , A61K31/4545 , A61K31/4965 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K45/06
Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
-
公开(公告)号:US20180028532A1
公开(公告)日:2018-02-01
申请号:US15672568
申请日:2017-08-09
Applicant: Novartis AG
Inventor: Jeffrey T. BAGDANOFF , Yu DING , Wooseok HAN , Zilin HUANG , Qun JIANG , Xianming JIN , Xiang KOU , Patrick LEE , Mika LINDVALL , Zhongcheng MIN , Yue PAN , Sabina PECCHI , Keith Bruce PFISTER , Daniel POON , Vivek RAUNIYAR , Xiaojing Michael WANG , Qiong ZHANG , Jianguang ZHOU , Shejin ZHU
IPC: A61K31/497 , A61K31/4433 , A61K31/5355 , A61K31/44 , A61K31/4436
CPC classification number: A61K31/497 , A61K31/44 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/4965 , A61K31/506 , A61K31/5355 , A61K31/5377 , A61K31/5383 , A61K31/553 , A61K45/06 , A61K2121/00 , C07D213/73 , C07D241/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D498/04
Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.
-
-
-
-
-
-
-
-
-